Development of Nasal Vaccine agaisnt RS virus based on neonatal innate immunity
Project/Area Number |
26670514
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Embryonic/Neonatal medicine
|
Research Institution | Osaka City University |
Principal Investigator |
Saito Mika 大阪市立大学, 大学院医学研究科, 講師 (40419700)
|
Co-Investigator(Kenkyū-buntansha) |
徳原 大介 大阪市立大学, 大学院医学研究科, 講師 (60448751)
|
Project Period (FY) |
2014-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
Keywords | ワクチン / アジュバント / 新生児 / 自然免疫 / RSウイルス / ウイルス / 臍帯血 / 感染症 |
Outline of Final Research Achievements |
Adjuvant is necessary for the development of vaccine against RSV, because the immune response against recombinant RSV protein is weak in neonates and adults. Zymosan, a cell wall extract from Saccharomyces cervisiae, gave comparable innate immune response via TLR2/TLR6 heterodimer in the immune cells of cord blood and adult blood, thus may be useful as a nasal vaccine adjuvant against RSV in neonates and infants.
|
Report
(4 results)
Research Products
(12 results)
-
-
-
[Journal Article] Zymosan induces immune responses comparable with those of adults in monocytes, dendritic cells, and monocyte-derived dendritic cells from cord blood2015
Author(s)
Kyoko Nohmi, Daisuke Tokuhara, Daisuke Tachibana, Mika Saito, Yuko Sakashita, Akemi Nakano, Hiroyuki Terada, Hiroko Yamamoto, Masayasu Koyama, Haruo Shintaku
-
Journal Title
Journal of Pediatrics
Volume: 印刷中
Related Report
Peer Reviewed / Acknowledgement Compliant
-
-
-
-
-
-
-
-
-